{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:58:03Z","timestamp":1793177883398,"version":"4.5.0"},"reference-count":143,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["J 4911-B"],"award-info":[{"award-number":["J 4911-B"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand up to Cancer","doi-asserted-by":"publisher","award":["6331"],"award-info":[{"award-number":["6331"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ccell.2026.01.001","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:36:07Z","timestamp":1769700967000},"page":"471-497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Emerging landscape of KRAS inhibitors in cancer treatment"],"prefix":"10.1016","volume":"44","author":[{"given":"Jakob M.","family":"Riedl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parasvi S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Fece de la Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doga C.","family":"Gulhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan B.","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2026.01.001_bib1","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The Frequency of Ras Mutations in Cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41388-023-02638-1","article-title":"Ras protein abundance correlates with Ras isoform mutation patterns in cancer","volume":"42","author":"Hood","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.ccell.2026.01.001_bib3","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1038\/sj.onc.1210956","article-title":"Partial functional overlap of the three ras genes in mouse embryonic development","volume":"27","author":"Nakamura","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ccell.2026.01.001_bib4","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/MCB.21.5.1444-1452.2001","article-title":"Targeted Genomic Disruption of H-ras and N-ras, Individually or in Combination, Reveals the Dispensability of Both Loci for Mouse Growth and Development","volume":"21","author":"Esteban","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ccell.2026.01.001_bib5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/sj.embor.7400397","article-title":"Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice","volume":"6","author":"Potenza","year":"2005","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ccell.2026.01.001_bib6","series-title":"Generation and Characterization of Triple Knockout Mice for H, N and K-Ras Genes","author":"Scala","year":"2008"},{"key":"10.1016\/j.ccell.2026.01.001_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","article-title":"Therapeutic strategies to target RAS-mutant cancers","volume":"15","author":"Ryan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2026.01.001_bib9","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ccell.2026.01.001_bib10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13402-022-00698-1","article-title":"A comprehensive review of SHP2 and its role in cancer","volume":"45","author":"Asmamaw","year":"2022","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib11","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/jcmm.12618","article-title":"Functions of Shp2 in cancer","volume":"19","author":"Zhang","year":"2015","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10555-008-9126-y","article-title":"The tyrosine phosphatase Shp2 (PTPN11) in cancer","volume":"27","author":"Chan","year":"2008","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ccell.2026.01.001_bib13","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.molcel.2024.07.024","article-title":"Functional and structural insights into RAS effector proteins","volume":"84","author":"Mozzarelli","year":"2024","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ccell.2026.01.001_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/science.adk0775","article-title":"Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers","volume":"384","author":"Klomp","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ccell.2026.01.001_bib15","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib16","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ccell.2026.01.001_bib17","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ccell.2026.01.001_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113497","article-title":"Precision medicine for KRAS wild-type pancreatic adenocarcinomas","volume":"197","author":"Ben-Ammar","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ccell.2026.01.001_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","article-title":"Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ccell.2026.01.001_bib20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.01.001_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.01.001_bib22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.01.001_bib23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib25","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2026.01.001_bib29","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-Human Phase I\/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib32","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2026.01.001_bib34","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO-25-00040","article-title":"Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study","volume":"43","author":"Sacher","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib35","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib36","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41591-024-03401-z","article-title":"Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial","volume":"31","author":"Shi","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2025.43.4_suppl.191","article-title":"Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer","volume":"43","author":"Li","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1200\/JCO.2024.42.3_suppl.604","article-title":"Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib39","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jtho.2024.08.005","article-title":"Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study","volume":"19","author":"Zhou","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib40","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1200\/JCO.2023.41.16_suppl.3586","article-title":"Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Preliminary results from a pooled analysis of two phase I studies","volume":"41","author":"Yuan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib41","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(24)00110-3","article-title":"Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial","volume":"12","author":"Li","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41392-025-02274-z","article-title":"Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation","volume":"10","author":"Ruan","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ccell.2026.01.001_bib43","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/s41591-025-03688-6","article-title":"D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial","volume":"31","author":"Cho","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib44","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2024.42.16_suppl.3007","article-title":"Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors","volume":"42","author":"Heist","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1200\/JCO.2024.42.3_suppl.94","article-title":"Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study","volume":"42","author":"Hollebecque","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib46","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1200\/JCO.2023.41.16_suppl.9007","article-title":"KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)","volume":"41","author":"Cassier","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib47","doi-asserted-by":"crossref","first-page":"8605","DOI":"10.1200\/JCO.2025.43.16_suppl.8605","article-title":"MK-1084 for KRAS G12C-mutated (mut) metastatic non\u2013small-cell lung cancer (mNSCLC): Results from KANDLELIT-001","volume":"43","author":"Sacher","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib48","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1200\/JCO.2025.43.16_suppl.3508","article-title":"The KRAS G12C inhibitor MK-1084 for KRAS G12C-mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001","volume":"43","author":"Lugowska","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib49","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/JCO.2025.43.16_suppl.8520","article-title":"Sosimerasib monotherapy in patients with previously treated KRAS G12C\u2013mutated non-small cell lung cancer: Primary results of a phase 2 study","volume":"43","author":"Zhong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","article-title":"Sotorasib with panitumumab in chemotherapy-refractory KRAS(G12C)-mutated colorectal cancer: a phase 1b trial","volume":"30","author":"Kuboki","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib51","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1200\/JCO-24-02026","article-title":"Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer","volume":"43","author":"Pietrantonio","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib52","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.01.001_bib53","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","article-title":"Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial","volume":"30","author":"Desai","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib54","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.2025.43.16_suppl.3507","article-title":"Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer","volume":"43","author":"Hollebecque","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib55","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2025.43.16_suppl.3506","article-title":"Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b)","volume":"43","author":"Strickler","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib56","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jtho.2022.07.025","article-title":"OA03.06 CodeBreaK 100\/101: First Report of Safety\/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC","volume":"17","author":"Li","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib57","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2025.43.16_suppl.8500","article-title":"First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced\/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study","volume":"43","author":"J\u00e4nne","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib58","doi-asserted-by":"crossref","first-page":"8519","DOI":"10.1200\/JCO.2025.43.16_suppl.8519","article-title":"Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial","volume":"43","author":"Dragnev","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib59","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ccell.2026.01.001_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107921","article-title":"Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation","volume":"196","author":"Waterhouse","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ccell.2026.01.001_bib61","doi-asserted-by":"crossref","first-page":"101591","DOI":"10.1016\/j.tranon.2022.101591","article-title":"Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?","volume":"28","author":"Olivier","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib62","doi-asserted-by":"crossref","first-page":"TPS8653","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8653","article-title":"Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)","volume":"42","author":"Barlesi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib63","doi-asserted-by":"crossref","first-page":"S349","DOI":"10.1016\/j.jtho.2024.09.629","article-title":"P3.12D.07 Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+ Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","volume":"19","author":"Gadgeel","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib64","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","article-title":"Exploiting the therapeutic implications of KRAS inhibition on tumor immunity","volume":"42","author":"Molina-Arcas","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.01.001_bib65","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib66","doi-asserted-by":"crossref","first-page":"S872","DOI":"10.1016\/j.annonc.2024.08.1449","article-title":"1394TiP KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation","volume":"35","author":"Garassino","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib67","doi-asserted-by":"crossref","first-page":"S571","DOI":"10.1016\/j.jtho.2025.09.1076","article-title":"P3.18.61 KRYSTAL-4: Phase 3 Study of Adagrasib Plus Pembrolizumab and Chemotherapy Intreatment-Naive, Advanced KRAG12C-Mutated NSCLC","volume":"20","author":"Naidoo","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib68","doi-asserted-by":"crossref","first-page":"TPS8656","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8656","article-title":"Krascendo 2: A phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC)","volume":"43","author":"Skoulidis","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib69","doi-asserted-by":"crossref","first-page":"TPS8649","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8649","article-title":"SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC","volume":"42","author":"Negrao","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib70","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1016\/j.jtho.2025.09.1025","article-title":"P3.18.09 SUNRAY-02: A Phase 3 Study of Olomorasib and Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC After Definitive Therapy","volume":"20","author":"Nadal","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib71","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41568-024-00679-6","article-title":"Combinatorial strategies to target RAS-driven cancers","volume":"24","author":"Perurena","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2026.01.001_bib72","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1200\/JCO.2023.41.16_suppl.3563","article-title":"Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I\/II study","volume":"41","author":"Ruan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib73","doi-asserted-by":"crossref","first-page":"S1512","DOI":"10.1016\/j.annonc.2023.10.241","article-title":"106P Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies","volume":"34","author":"Yuan","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib74","doi-asserted-by":"crossref","first-page":"110993","DOI":"10.1016\/j.celrep.2022.110993","article-title":"KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy","volume":"39","author":"Ryan","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ccell.2026.01.001_bib75","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.01.001_bib76","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS(G12C) Inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib77","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib78","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.annonc.2021.05.126","article-title":"P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation","volume":"32","author":"Tabernero","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib79","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1016\/j.annonc.2024.08.574","article-title":"505O Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study","volume":"35","author":"Siena","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib80","first-page":"TPS326","article-title":"A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C-mutated metastatic colorectal cancer (CodeBreaK 301)","volume":"43","author":"Kim","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib81","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A Phase 2 Trial of Ponatinib in Philadelphia Chromosome\u2013Positive Leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib82","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib83","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/cas.16441","article-title":"Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt","volume":"116","author":"Tanaka","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ccell.2026.01.001_bib84","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/2159-8290.CD-25-0349","article-title":"Response and Resistance to RAS Inhibition in Cancer","volume":"15","author":"Ebright","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.01.001_bib85","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.01.001_bib86","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.01.001_bib87","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-24-2310","article-title":"Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial","volume":"31","author":"Negrao","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib88","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1038\/s41591-025-03732-5","article-title":"Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer","volume":"31","author":"Skoulidis","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib89","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib90","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.annonc.2025.01.020","article-title":"Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors","volume":"36","author":"Riedl","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib91","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.01.001_bib92","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRASG12C Inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib93","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","article-title":"Molecular Characterization of Acquired Resistance to KRASG12C\u2013EGFR Inhibition in Colorectal Cancer","volume":"13","author":"Yaeger","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.01.001_bib94","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41571-025-01011-3","article-title":"Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials","volume":"22","author":"Ernst","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib95","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.01.001_bib96","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.01.001_bib97","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical Acquired Resistance to KRAS(G12C) Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.01.001_bib98","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.adg9652","article-title":"Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS","volume":"381","author":"Schulze","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.ccell.2026.01.001_bib99","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1158\/1078-0432.CCR-18-0368","article-title":"KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition","volume":"25","author":"Misale","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib100","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR Blockade Reverts Resistance to KRAS(G12C) Inhibition in Colorectal Cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.01.001_bib101","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.01.001_bib102","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s43018-023-00575-2","article-title":"Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS","volume":"4","author":"Adachi","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ccell.2026.01.001_bib103","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","article-title":"An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance","volume":"4","author":"Hagenbeek","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ccell.2026.01.001_bib104","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","article-title":"Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer","volume":"26","author":"Adachi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2159-8290.CD-23-0289","article-title":"Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma","volume":"14","author":"Li","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.01.001_bib106","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","article-title":"Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer","volume":"42","author":"Tong","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.01.001_bib107","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.annonc.2025.01.020","article-title":"Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors","volume":"36","author":"Riedl","year":"2025","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib108","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ccell.2026.01.001_bib109","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1021\/acs.jmedchem.4c02313","article-title":"Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ccell.2026.01.001_bib110","doi-asserted-by":"crossref","first-page":"PR014","DOI":"10.1158\/1535-7163.TARG-23-PR014","article-title":"Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment","volume":"22","author":"J\u00e4nne","year":"2023","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ccell.2026.01.001_bib111","doi-asserted-by":"crossref","first-page":"CT019","DOI":"10.1158\/1538-7445.AM2025-CT019","article-title":"Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors","volume":"85","author":"Arbour","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib112","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1200\/JCO.2025.43.4_suppl.724","volume":"43","author":"Spira","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib113","first-page":"S1741","article-title":"LBA84 Efficacy and safety of GFH375 monotherapy in previously treated advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC)","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib114","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.jtho.2025.09.110","article-title":"MA02.07 Efficacy and Safety of GFH375 in Advanced Non-small Cell Lung Cancer Patients with KRAS G12D Mutation","volume":"20","author":"Lu","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib115","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1016\/j.annonc.2025.08.1484","article-title":"915O KRAS G12D inhibitor HRS-4642 in patients with KRAS G12D-mutant advanced solid tumors: A phase I trial","volume":"36","author":"Xiong","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib116","doi-asserted-by":"crossref","first-page":"S597","DOI":"10.1016\/j.annonc.2025.08.1485","article-title":"916O Preliminary phase I results of INCB161734, a novel oral KRAS G12D inhibitor, in patients with advanced or metastatic solid tumors","volume":"36","author":"Desai","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib117","series-title":"Efficacy and safety of ASP3082, a novel protein degrader, as monotherapy in patients (pts) with non-small cell lung cancer (NSCLC) with KRAS G12D mutation. held in Boston, MA","author":"Spira","year":"2025"},{"key":"10.1016\/j.ccell.2026.01.001_bib118","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1200\/JCO.2025.43.4_suppl.722","article-title":"Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)","volume":"43","author":"Garrido-Laguna","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib119","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S1556-0864(25)00201-1","article-title":"6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)","volume":"20","author":"Punekar","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib120","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1158\/2159-8290.CD-24-0840","article-title":"Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C","volume":"15","author":"Maciag","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.01.001_bib121","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1538-7445.AM2023-1142","article-title":"Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C","volume":"83","author":"Patel","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib122","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.01.001_bib123","doi-asserted-by":"crossref","DOI":"10.1126\/science.ads0239","article-title":"A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors","volume":"389","author":"Weller","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.ccell.2026.01.001_bib124","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1158\/1538-7445.AM2025-4394","article-title":"Abstract 4394: GFH375 (VS-7375): An oral, selective KRAS G12D (ON\/OFF) inhibitor with potent anti-tumor efficacy as single agent and in combination with other anticancer therapies in preclinical models","volume":"85","author":"Pachter","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib125","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","article-title":"Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.01.001_bib126","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1158\/1538-7445.AM2024-5900","article-title":"Abstract 5900: INCB161734: A novel, potent, and orally bioavailable KRAS G12D selective inhibitor demonstrates antitumor activity in KRAS G12D mutant tumors","volume":"84","author":"Farren","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib127","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1158\/1538-7445.AM2023-5735","article-title":"Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models","volume":"83","author":"Nagashima","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib128","doi-asserted-by":"crossref","first-page":"ND06","DOI":"10.1158\/1538-7445.AM2025-ND06","article-title":"Abstract ND06: Discovery of RMC-5127, an oral, RAS (ON) G12V-selective, noncovalent, tri-complex inhibitor","volume":"85","author":"Edwards","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib129","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1158\/1538-7445.AM2023-1598","article-title":"Abstract 1598: RM-046, a first-in-class, mutant-selective, and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target","volume":"83","author":"Yang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib130","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1158\/1538-7445.AM2022-3598","article-title":"Abstract 3598: A first-in-class tri-complex KRASG13C(ON) inhibitor validates therapeutic targeting of KRASG13Cand drives tumor regressions in preclinical models","volume":"82","author":"Schulze","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib131","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/s41589-022-01065-9","article-title":"Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S)","volume":"18","author":"Zhang","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ccell.2026.01.001_bib132","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","article-title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","volume":"629","author":"Holderfield","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.01.001_bib133","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41586-024-08283-2","article-title":"Pharmacological restoration of GTP hydrolysis by mutant RAS","volume":"637","author":"Cuevas-Navarro","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.01.001_bib134","doi-asserted-by":"crossref","first-page":"LB281","DOI":"10.1158\/1538-7445.AM2025-LB281","article-title":"Abstract LB281: Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies","volume":"85","author":"Kar","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib135","article-title":"Mechanisms of resistance to active state selective tri-complex RAS inhibitors","author":"Sang","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.ccell.2026.01.001_bib136","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1538-7445.AM2025-390","article-title":"Abstract 390: ERAS-0015 is a pan-RAS molecular glue with best-in-class potential in RAS mutant solid tumors","volume":"85","author":"Lew","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib137","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1158\/1535-7163.MCT-24-0386","article-title":"Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification","volume":"24","author":"Tedeschi","year":"2025","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ccell.2026.01.001_bib138","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1126\/science.1144642","article-title":"Network analysis of oncogenic Ras activation in cancer","volume":"318","author":"Stites","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ccell.2026.01.001_bib139","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1200\/JCO.2025.43.16_suppl.3013","article-title":"A first-in-human phase I\/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors","volume":"43","author":"Ai","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib141","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non\u2013Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.001_bib142","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2026.01.001_bib143","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1158\/1078-0432.CCR-14-1213","article-title":"Intratumoral Heterogeneity: From Diversity Comes Resistance","volume":"21","author":"Pribluda","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.001_bib144","first-page":"531","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"30","author":"Wainberg","year":"2025","journal-title":"Nat. Med."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:28:16Z","timestamp":1791347296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610826000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":143,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1535610826000103"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2026.01.001","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging landscape of KRAS inhibitors in cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}